It remains unclear whether surgical or transcatheter mitral valve repair for secondary mitral regurgitation (MR) in patients with non-ischaemic cardiomyopathy reverse the underlying left ventricular (LV) pathophysiology. We hypothesized that mitral valve repair improves LV systolic function and forward flow and induces LV reverse remodelling in this group of patients. 
Introduction
Secondary mitral regurgitation (MR) in patients with non-ischaemic dilated cardiomyopathy is associated with poor survival. 1 Despite optimal medical therapy and current device therapies, severe secondary MR confers worse prognosis and the outcomes of surgical mitral valve repair remain controversial. Accordingly, current European Society of Cardiology and American Heart Association/American College of Cardiology guidelines consider mitral valve repair in this group of patients as class IIb recommendation. transcatheter mitral valve repair procedures have provided alternative therapy for patients with increased surgical risk such as patients with non-ischaemic cardiomyopathy and reduced left ventricular ejection fraction (LVEF). 4, 5 It remains unknown whether surgical or transcatheter mitral valve repair techniques may alter the underlying left ventricular (LV) pathophysiology in non-ischaemic secondary MR and prevent further LV dilation and dysfunction. In non-ischaemic cardiomyopathy, LV remodelling with displacement of the papillary muscles toward more apical positions and tethering of the mitral leaflets causes MR which leads to progressive LV remodelling and begets MR. It is logical to hypothesize that by restoring the mitral valve competence, LV remodelling may be halted and even reversed, improving LV systolic function, and clinical prognosis. However, current data reporting on LV remodelling and functional recovery after mitral valve repair for secondary MR concern mainly ischaemic cardiomyopathy patients and the results are controversial. [5] [6] [7] Accordingly, we hypothesized that mitral valve repair for secondary MR in non-ischaemic dilated cardiomyopathy, results in LV reverse remodelling (reduction in LV end-diastolic, and end-systolic volume index), increase of forward flow (increase in stroke volume index and cardiac output) and improvement of LV systolic function (increase in LVEF and global longitudinal strain/LV end-diastolic volume).
Methods Patients
Patients with non-ischaemic heart failure and moderate to severe secondary MR who underwent surgical or transcatheter mitral valve repair were retrospectively identified from a clinical database (EPD-vision 8.3.3.6; Leiden University Medical Center, Leiden, The Netherlands). Patients who underwent concomitant aortic valve replacement or LV cardiac support device implantation (CorCap, Acorn Cardiovascular, St. Paul, Minnesota) were excluded. Successful mitral valve repair was defined as residual MR grade < _2 at discharge. 8 None of the patients included in the current analysis was re-operated for severe MR during the follow-up period. Demographics, clinical, and procedural information and echocardiographic data were retrospectively analysed from the departmental clinical (EPD-vision 8.3.3.6; Leiden, The Netherlands) and echocardiographic (EchoPAC version 112.0.1; GE Vingmed Ultrasound, Norway) databases.
Mitral valve repair procedures
The type of mitral valve repair (surgical restrictive annuloplasty or transcatheter MitraClip implantation [Abbott Vascular, Venlo, CA, USA]) was decided by the Heart Team, based on patient's characteristics (symptoms, comorbidities, frailty), logistic EuroSCORE and the anatomical suitability for MitraClip implantation. 9 Transcatheter mitral valve repair with the MitraClip device started in 2011 at the Leiden University Medical Center. Surgical mitral valve repair was performed using restrictive mitral ring annuloplasty. 10 The mitral valve annulus was measured and the mitral ring (Carpentier Edwards Physioring, Edwards Lifesciences, Irvine, CA) was implanted, downsizing the ring by two sizes. 10 Transcatheter implantation of the MitraClip system uses a 24-F torqueable sheath which is introduced through the femoral vein into the right atrium passing to the left atrium through a trans-septal puncture. 11, 12 The procedure is performed under the guidance of 2-and 3-dimensional transoesophageal echocardiography and the immediate reduction in MR is evaluated. 9 More than one clip can be implanted in order to achieve adequate correction of MR without significant increase in diastolic transmitral gradient. 13 
Echocardiography
Transthoracic echocardiography was performed at baseline, before discharge and at mid-term follow-up (6 month), using a commercially available ultrasound system (Vivid 7 and Vivid E9; GE Vingmed Ultrasound AS, Horten, Norway) equipped with 3.5-MHz or M5S transducers. Twodimensional grey scale images and colour, continuous-wave, and pulsewave Doppler data were digitally stored and were analysed offline (EchoPAC version 112.0.1; GE Vingmed Ultrasound, Norway). Mitral regurgitation severity was assessed by an integrated approach as recommended, including measurement of the vena contracta and quantification of the effective regurgitant orifice area and regurgitant volume with the proximal isovelocity surface area method. 14 , and a regurgitant volume of > _30 mL/beat. 14, 15 The residual MR post-repair was quantified in a semi-quantitative method as previously reported. 8, 12 LV remodelling was evaluated according to current recommendations. 16 LV end-diastolic and end-systolic volumes were evaluated by Simpsons' biplane method and then indexed to body surface area. LV dimensions were measured on the parasternal long-axis view and the LV mass was calculated and indexed to body surface area, as previously described. 16 In addition, the relative wall thickness ([2 x posterior wall thickness in diastole]/LV end-diastolic diameter) and the ratio of LV mass to LV end-diastolic volume were also assessed. 16 LVEF was measured using the Simpsons' biplane method. 16 Additionally, LV systolic function was assessed by 2-dimensional speckle tracking systolic global longitudinal strain (GLS). 17 GLS was evaluated at the apical 3-, 4-, and 2-chamber views after defining the aortic valve closure timing on the 3-chamber view. 17 Subsequently, GLS was corrected for LV end-diastolic volume (every 10 mL) as previously reported. 18 LV pressure and strain are affected by the LV myocardial fibers' length, according to the Frank-Starling law, 19 and as a result when the LV size changes due to MR reduction post-repair, the GLS should be corrected for the LV size. 18, 20 Furthermore, LV forward stroke volume was estimated by multiplying the LV outflow tract cross-sectional area by the velocity time integral derived from the pulse-wave Doppler signal of the LV outflow tract and indexed to body surface area. The cardiac output was calculated from the stroke volume multiplied by the heart rate and the cardiac index by the cardiac output indexed to body surface area. The LV forward ejection fraction was estimated by dividing the stroke volume by the LV end-diastolic volume and expressed as a percentage. 18 
Statistical analysis
A minimum of 62 patients were necessary to be included in order to have a power of the analysis of 80% (alpha 0.05 and effect size 0.25). The continuous variables are presented as mean ± standard deviation and the categorical variables as frequencies and percentages. The continuous variables were compared with unpaired Students t-test or Mann-Whitney U test as appropriate. The categorical variables were compared with the chi-square test. Changes over time in LV function variables (LVEF, GLS, corrected GLS), forward flow variables (stroke volume, stroke volume index, cardiac output, cardiac index, LV forward ejection fraction), and LV remodelling variables (LV end-diastolic volume, end-systolic volume, mass, relative wall thickness, ratio mass/end-diastolic volume) were assessed using linear mixed models analysis with all these variables as dependent variables. Time (baseline, pre-discharge, and 6 months) and type of repair (MitraClip or surgical repair) were introduced as main fixed effects. Main effects were compared and their interaction was tested using the Bonferroni confidence interval adjustment. Post-hoc analysis was performed with the Bonferroni test to determine the time points at which the dependent variables significantly differed.
All statistical analyses were performed with the SPSS version 20 (SPSS, Inc, Chicago, IL) and P values <0.05 were considered statistically significant.
Results

Baseline characteristics
In total, 76 patients (65 ± 14 years old, 43% male) with severe secondary MR and non-ischaemic dilated cardiomyopathy with LVEF <50% who were successfully treated with mitral valve repair were evaluated. Surgical mitral valve repair was performed in 54 (71%) patients whereas 22 (29%) were treated with transcatheter MitraClip implantation. In the surgical group, 41 (76%) patients underwent concomitant tricuspid valve annuloplasty. Cardiac resynchronization therapy was used in 20 (26%) patients; 11 of them (55%) had MitraClip treatment and 9 (45%) surgical repair.
Patients treated with the MitraClip device were older, had more often diabetes, hypertension, renal failure, and showed more advanced heart failure symptoms compared with patients surgically treated ( Table 1) . Baseline MR vena contracta, effective regurgitant orifice area and regurgitant volume were 0.63 ± 0.16 cm, 0.21 ± 0.10 cm 2 , and 32 ± 12 mL, respectively, and were comparable between the two treatment groups ( Table 2 ). The parameters characterizing LV function, LV forward flow and remodelling are presented in Table 3 . Patients treated with the MitraClip device had more dilated and eccentrically hypertrophied LV but comparable systolic function and LV forward flow than patients treated with surgical repair.
MR change post-repair
Repeated echocardiography was performed pre-discharge (median of 5 days; interquartile range 1-7) and at mid-term follow-up (median of 6 months; interquartile range 4-9). The MR grade at discharge was by definition < _2, and although it increased at mid-term follow-up, it was still significantly less severe compared with baseline (P < 0.001) (Figure 1) . Specifically, at mid-term follow-up, in the surgical repair group 38% had no MR, 45% MR grade 1, and 17% MR grade 2 and in the MitraClip group 5% had no MR, 47% MR grade 1, 26% MR grade 2, and 21% MR grade 3. MR at follow-up was significantly less severe than pre-repair in both groups (P < 0.001 in both groups). At midterm follow-up, patients with MR grade <2 had significantly better LV function and forward ejection fraction and smaller LV volumes as compared with their counterparts ( Table 4) .
LV functional recovery, forward flow, and remodelling post-repair Over time after successful repair, LVEF and corrected GLS remained unchanged (P = 0.90 and P = 0.96, respectively) ( Table 5 ). However, LV forward flow assessed by stroke volume index, cardiac output, cardiac index and LV forward ejection fraction increased over time (P < 0.001 for all parameters). This increase was detected at discharge and although at mid-term follow-up all these parameters were significantly reduced compared with discharge values, they still remained significantly better compared with baseline (follow-up vs. baseline Bonferroni P < 0.001 for all the forward flow parameters) ( Table 5) .
There were significant reductions in LV end-diastolic and endsystolic volumes over time after mitral valve repair (P < 0.001 and P = 0.005, respectively). This reduction occurred immediately after the MV repair at discharge and was sustained at mid-term follow-up (follow-up vs. baseline Bonferroni P = 0.001 and P = 0.004, respectively) ( Table 5) . Differences between treatment group are presented in Supplementary data online, Tables S1 and S2. 
Impact of the type of repair on LV functional recovery, forward flow, and remodelling
Over time, the type of repair (MitraClip or surgical) had no impact on LVEF change (coefficient -3.50, 95% CI -8.61-1.54, P = 0.17) and corrected GLS change (coefficient -1.48, 95% CI -4.64-1.67, P = 0.35). Moreover, the type of repair had no impact on stroke volume index change (coefficient -1.97, 95% CI -4.81-0.87, P = 0.17) and cardiac index change over time (coefficient -0.13, 95% CI -0.33-0.08, P = 0.21). As a result, the type of repair had no impact on LV functional recovery and forward flow change over time ( Figure 2) . Furthermore, patients treated with the MitraClip device had larger LV end-diastolic and end-systolic volume index (coefficient 29.38, 95% CI 11.17-47.59, P = 0.002 and coefficient 22.17, 95% CI 5.15-39.20, P = 0.01, respectively) and LV mass index (coefficient 25.40, 95% CI 5.50-45.30, P = 0.01) compared with the surgical repair group. However, LV reverse remodelling was comparable in both treatment groups (P for interaction 0.46 and 0.65, respectively). In addition, the type of repair had no impact on the relative wall thickness change (coefficient 0.05, 95% CI -0.03-0.04, P = 0.96) or reduction in LV mass (P for interaction 0.88) (Figure 3 ). This indicates that both therapies exerted similar LV reverse remodelling over time ( Figure 3 ).
Discussion
The current study shows that successful correction of chronic moderate to severe secondary MR in non-ischaemic dilated cardiomyopathy patients partly reverses the underlying LV pathophysiology, with significant increase of LV forward flow and LV reverse remodelling but without changes in LVEF and GLS over time. 
LV functional recovery after mitral valve repair
Despite the heterogeneous patient populations (ischaemic vs. nonischaemic) and the different surgical repair techniques used (isolated mitral valve repair vs. associated with coronary artery bypass grafting or LV reconstruction or passive containment with cardiac support devices), the majority of the studies showed modest but statistically significant improvements in LVEF after surgical mitral valve repair for secondary MR. 21 Among the studies including patients with nonischaemic secondary MR, the Acorn trial, where almost 78% of patients had non-ischaemic cardiomyopathy, showed significant and sustained improvements in LVEF at 12 months after restrictive mitral valve annnuloplasty. 22 In contrast, a study including 69 patients with non-ischaemic cardiomyopathy undergoing restrictive mitral valve annuloplasty showed no significant improvement in LVEF (from 26 ± 8 to 29 ± 11% at 2-year follow-up). 23 Using MitraClip device several series have reported conflicting results in terms of LVEF improvement during follow-up. 5, 24 The Real World Expanded
Multicenter Study of the MitraClip System (REALISM) study including 379 patients with secondary MR (12.2% non-ischaemic aetiology) showed stable LVEF at 12 months follow-up after MitraClip (44 ± 11 vs. 44 ± 11%). 5 In contrast, the sub-analysis of the Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation (GRASP) registry, including 78 patients (about 62% non-ischaemic) with secondary MR, reported significant improvement of the LVEF 12-months post-MitraClip (from 40.72 ± 11.62 to 46.23 ± 9.03%). 24 In these studies, disparities in patient populations may explain in part the controversial results in terms of LVEF improvement. However, LVEF may not be the best reflector of improvement in LV systolic function after mitral valve repair. In 24 patients with secondary MR (54% non-ischaemic cardiomyopathy) who underwent cine multi-detector row computed tomography prior to and 2 months after restrictive mitral annuloplasty, Takeda et al. showed an 11% decrease in global LV end-systolic wall stress along with significant improvement in LVEF (from 27 ± 8% to 33 ± 13%; P = 0.0007) and LV reverse remodelling (21% and 13% reductions in LV endsystolic and end-diastolic volumes, respectively). 25 This reduction in LV end-systolic volume would lead to a reduction in LV end-systolic wall stress favouring further reduction in LV systolic volume and exceeding the reduction in LV end-diastolic volume which eventually results in increase in LVEF. In addition, a modest improvement in LV end-systolic wall stress corrected for LV end-systolic volume (a relatively load-independent measure of myocardial contractility) was observed but was weakly correlated with the increase in LVEF suggesting that the improvement in LV ejection performance is most probably related to afterload reduction rather than intrinsic improvement in LV contractility. Similarly, the present study showed no changes in LV GLS corrected for end-diastolic volume. In contrast, improvement in LV forward ejection fraction was observed suggesting that restrictive mitral annuloplasty is not associated with improvements in LV contractility but with significant reductions in afterload.
LV reverse remodelling after mitral valve repair
The prevalence of LV reverse remodelling, defined as 15% reduction in LV end-systolic volume, after surgical mitral valve repair for secondary MR ranges between 50% and 73%. 23, 26, 27 In studies including patients in whom passive restraint devices were used (i.e. CorCap Acorn CV, St Paul, Minn), the magnitude of LV volumes reduction was higher compared with series where these devices were not used. 22, 23 The Acorn trial showed significant and sustained reductions in LV end-systolic and end-diastolic volumes at 5 years after restrictive mitral annuloplasty. 22 Using the MitraClip device, Glower et al. reported the 12-month echocardiographic outcomes of 351 patients enrolled in the EVEREST-II (Endovascular Valve Edge-to-Edge REpair Study) High-Risk registry and the REALISM Continued Access Study High-Risk Arm: 4 the LV end-diastolic volume reduced from 161 ± 56 mL to 143 ± 53 mL (P < 0.001) and end-systolic volume from 87 ± 47 mL to 79 ± 44 mL (P < 0.001). In the present study, both LV end-diastolic and end-systolic volume decreased significantly at follow-up. Interestingly, patients treated with the MitraClip device showed larger LV volumes during follow-up as compared with patients who underwent surgical mitral valve repair. It has been described that the presence of significant residual MR or recurrent MR is associated with less LV reverse remodelling. 5 In line with previous studies, 28 ,29 the present study also showed that the prevalence of moderate MR in this study was significantly higher in the MitraClip group at discharge (MR grade 2: 27% vs. 0%, P < 0.001) and at followup (MR grade 2-3: 47% vs. 17%, P = 0.02) compared with the surgical repair group. However, the type of treatment was not associated with the occurrence of LV reverse remodelling. Probably other confounding parameters, apart from the gradual MR increase, may influence this finding.
5
Clinical implications: does mitral valve repair reverse the underlying pathophysiology of non-ischaemic secondary MR
The current analysis demonstrated that LV reverse remodelling and LV forward flow increased after mitral valve repair in patients with non-ischaemic secondary MR and these improvements were independent of the type of repair (surgical or transcatheter). Current guidelines indicate that mitral valve repair/replacement may be considered in non-ischaemic heart failure patients with symptomatic severe secondary MR despite optimal medical treatment (including cardiac resynchronization therapy) (Class IIbC) due to the limited evidence and the inconsistent results in terms of clinical and echocardiographic outcomes across the various studies. 2, 3 The present study provides further insights into the question on the effects of mitral valve repair on the underlying pathophysiology of non-ischaemic secondary MR by showing that, despite no changes in LVEF or GLS corrected for LV end-diastolic volume, LV reverse remodelling occurs, and LV forward ejection fraction improves. The fact that these findings were independent of type of repair emphasizes the relevance of the role of the Heart team which is able to personalize the treatment according to the surgical risk.
Limitations
The current analysis included a relatively small number of patients which precluded us to perform survival analyses. However, the cohort was very homogeneous including only patients with non-ischaemic secondary MR. Longer follow-up would have strengthened the results by showing whether changes in LV structure and function were sustained.
Conclusion
Successful correction of chronic moderate to severe secondary MR in non-ischaemic dilated cardiomyopathy patients partly reverses the underlying LV pathophysiology, with significant increase of LV forward flow and LV reverse remodelling but without changes in LVEF and corrected-GLS over time.
Supplementary data
Supplementary data are available at European Heart Journal-Cardiovascular Imaging online. 
